Φορτώνει......
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
BACKGROUND: Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20–30% of treated patients present long term benefits. The metabolic changes occurring in the gut microbiota metabolome are herein proposed as a factor potentially influencing the response to immunotherapy. METHODS: The...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Transl Med |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6998840/ https://ncbi.nlm.nih.gov/pubmed/32014010 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02231-0 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|